Anticoagulants - Market Insights & Drugs Sales Forecast (VTE & AF) - 2020

  • ID: 3693114
  • Drug Pipelines
  • Region: Global
  • 121 pages
  • DelveInsight
1 of 4
Global Anticoagulants (VTE & AF) Therapeutics Market Was around $11.4 Billion in 2015 and Is Estimated to Reach $17.2 Billion by 2020

FEATURED COMPANIES

  • Aspen Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squib
  • Daiichi Sankyo
  • Glaxosmithkline
  • MORE
"The Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020report provides an overview of the disease, epidemiology and global market trends for the seven major markets ie: United States, EU5 (France, Germany, Italy, Spain, UK) and Japan.

Coagulation is an important phenomenon of body to stop external bleeding but when clots are formed in blood vessels, it can be lethal. Blood clots in arteries can lead to heart attack and when formed in the blood vessels of brain can lead to stroke. Thus, anticoagulants are used to prevent the formation of blood clots in the body. Anticoagulants are proved to be a beneficial medication for the treatment of Atrial fibrillation, Deep Vein Thrombosis, Pulmonary Embolism and Stroke.

Globally the overall incidence for Venous Thromboembolism (VTE) and Atrial fibrillation (AF) is increasing at a higher rate. For VTE, there are approximately 1 million cases in the United States each year, many of which represent recurrent disease and AF affects approximately 3 million patients in the US, and over 6.7 million in the US and Europe combined.

Key Coverage and Benefits:
- The report will help in developing business strategies by understanding the trends shaping and driving the global Venous Thromboembolism (VTE) market.
- Identifying patient populations in the global Venous Thromboembolism (VTE) market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the best opportunities for Venous Thromboembolism (VTE) therapeutics in each of the markets covered.
- To understand the future market competition in the global Venous Thromboembolism (VTE) therapeutics market and Insightful review of the key market drivers and barriers.

Scope of the Report:

- Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management, and current treatment options.
- Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
- The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5, Japan and rest of the word from 2015-2020.
- It also provides Venous Thromboembolism (VTE) for United States, EU5 and Japan from 2015 and forecasted Market to 2020.

*** Please note this report will take 48 hours to be dispatched ***
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Aspen Pharmaceuticals
  • Bayer
  • Boehringer Ingelheim
  • Bristol-Myers Squib
  • Daiichi Sankyo
  • Glaxosmithkline
  • MORE
Chapter 1 Anticoagulants Introduction
- Warfarin
- Low Molecular Weight Heparins
- New Oral Anticoagulants (NOAC)

Chapter 2 Venous Thromboembolism
- Disease Overview
- Epidemiology of Venous Thromboembolism
- Treatment Landscape
- Treatment Algorithm
- Treatment Goals
- Treatment Details

Chapter 3 Atrial Fibrillation
- Disease Overview
- Epidemiology of Atrial Fibrillation
- Treatment Landscape
- Treatment Algorithm
- Treatment Goals
- Treatment Details

Chapter 4 Key Marketed Anticoagulants
- Novel Oral Anticoagulants Comparison
- Reversal Agents (Antidotes)

Chapter 5 Anticoagulants Market Assessment
- Key Findings
- Global Anticoagulants Sales
- Global Anticoagulants Market by Drugs
- Global Anticoagulants Market Share (%)
- Global Anticoagulants Market Sales by Atrial Fibrillation (AF)
- Global Anticoagulants Market Share (%) in Atrial Fibrillation
- Global Anticoagulants Market Sales by Venous Thromboembolism
- Global Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 6 United States Anticoagulants Market Assessment
- Key Findings
- United States Anticoagulants Market
- United States Anticoagulants Market Share (%)
- United States Anticoagulants Market Sales by Atrial Fibrillation
- United States Anticoagulants Market Share (%) in Atrial Fibrillation
- United States Anticoagulants Market Sales by Venous Thromboembolism
- United States Anticoagulants Market Share (%) in Venous
- Thromboembolism

Chapter 7 Europe 5 Anticoagulants Market Assessment
- Key Findings
- Europe 5 Anticoagulants Market
- Europe 5 Anticoagulants Market Share (%)
- Europe 5 Anticoagulants Market Sales by Atrial Fibrillation
- Europe 5 Anticoagulants Market Share (%) in Atrial Fibrillation
- Europe 5 Anticoagulants Market Sales by Venous Thromboembolism
- Europe 5 Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 8 Japan Anticoagulants Market Assessment
- Key Findings
- Japan Anticoagulants Market
- Japan Anticoagulants Market Share (%)
- Japan Anticoagulants Market Sales by Atrial Fibrillation
- Japan Anticoagulants Market Share (%) in Atrial Fibrillation
- Japan Anticoagulants Market Sales by Venous Thromboembolism
- Japan Anticoagulants Market Share (%) in Venous Thromboembolism

Chapter 9 Xarelto (rivaroxaban) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Xarelto
- Safety of Xarelto
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Xarelto Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Xarelto Historical Sales and Forecasted Sales (2011-2020) by AF
- Xarelto Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trials Information
- SWOT Analysis of Xarelto

Chapter 10 Pradaxa (dabigatran etexilate mesylate) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Pradaxa
- Safety of Pradaxa
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Pradaxa Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Pradaxa Historical Sales and Forecasted Sales (2011-2020) by AF
- Pradaxa Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Pradaxa

Chapter 11 Eliquis(Apixaban) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy and Safety of Eliquis
- Side effects of Eliquis
- Cost of Therapy
- Global Drug Sales
- Eliquis Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Eliquis Historical Sales and Forecasted Sales (2011-2020) by AF
- Eliquis Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information

Chapter 12 Savaysa (edoxaban tosylate) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Savaysa
- Safety of Savaysa
- Side Effects of Savaysa
- Cost of Therapy
- Global Drug Sales
- Savaysa Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Savaysa Historical Sales and Forecasted Sales (2011-2020) by AF
- Savaysa Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Savaysa

Chapter 13 Lovenox (enoxaparin) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Safety and Efficacy of Lovenox
- Side effects of Lovenox
- Cost of Therapy
- Global Drug Sales
- Lovenox Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication (20%)
- Lovenox Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Lovenox

Chapter 14 Fraxiparine
- Product Profile
- Advantages & Disadvantages
- Safety and Efficacy of Fraxiparine
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Fraxiparine Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Fraxiparine Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trials Information
- SWOT Analysis of Fraxiparine

Chapter 15 Arixtra (Fondaparinux) Drug Profile
- Product Profile
- Advantages & Disadvantages
- Efficacy of Arixtra
- Safety of Arixtra
- Side effects of Drugs
- Cost of Therapy
- Global Drug Sales
- Arixtra Historical Sales and Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Arixtra Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trial Information
- SWOT Analysis of Arixtra

Chapter 16 Betrixaban Drug Profile
- Product Profile
- Advantages & Disadvantages
- Safety and Efficacy
- Side effects of Drugs
- Expected Cost of Therapy
- Global Drug Sales
- Betrixaban Forecasted Sales (2011-2020)
- Global Drug Sales by indication
- Betrixaban Historical Sales and Forecasted Sales (2011-2020) by VTE
- Clinical Trials Information

Chapter 17 Market Drivers and Constraints
- Factors Driving the Market Growth
- Factors Constraining the Market Growth
- Consulting Services
- Disclaimer

List of Tables

- Table 1: Key Marketed Anticoagulants
- Table 2: Comparison of NOACs & Warfarin
- Table 1: Global Anticoagulants Sales- 2015-2020 (USD MM)
- Table 2: Global Anticoagulants Sales by Drugs- 2011-2020 (USD MM)
- Table 3: Global Anticoagulants Sales by Drugs- 2015-2020 (USD MM)
- Table 4: Global Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 5: Global Anticoagulants Sales in Atrial Fibrillation – 2015-2020 (USD MM)
- Table 6: Global Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 7: Global Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
- Table 8: US Anticoagulants Sales- 2011-2020 (USD MM)
- Table 9: US Anticoagulants Sales- 2015-2020 (USD MM)
- Table 10: US Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 11: US Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
- Table 12: US Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 13: US Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
- Table 14: EU5 Anticoagulants Sales- 2011-2020 (USD MM)
- Table 15: EU5 Anticoagulants Sales- 2015-2020 (USD MM)
- Table 16: EU5 Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 17: EU5 Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
- Table 18: EU5 Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 19: EU5 Anticoagulants Sales in Venous Thromboembolism – 2015-2020 (USD MM)
- Table 20: Japan Anticoagulants Sales- 2011-2020 (USD MM)
- Table 21: Japan Anticoagulants Sales- 2015-2020 (USD MM)
- Table 22: Japan Anticoagulants Sales in Atrial Fibrillation 2011-2020 (USD MM)
- Table 23: Japan Anticoagulants Sales in Atrial Fibrillation - 2015-2020 (USD MM)
- Table 24: Japan Anticoagulants Sales in Venous Thromboembolism 2011-2020 (USD MM)
- Table 25: Japan Anticoagulants Sales in Venous Thromboembolism - 2015-2020 (USD MM)
- Table 26: Xarelto Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 29: Xarelto Sales by Atrial Fibrillation (AF) (USD MM)
- Table 27: Xarelto Sales by Venous Thromboembolism (VTE) (USD MM)
- Table 29: Xarelto, Clinical Trials by Zone, 2016
- Table 30: Pradaxa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 33:Pradaxa Sales by Atrial Fibrillation (AF) (USD MM)
- Table 34: Pradaxa Sales by Venous Thromboembolism (VTE) (USD MM)
- Table 33: Pradaxa, Clinical Trials by Zone, 2016
- Table 34: Eliquis Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 37:Eliquis Sales by Atrial Fibrillation (AF) (USD MM)
- Table 35: Eliquis Sales by Venous Thromboembolism (VTE) (USD MM)
- Table 37: Eliquis, Clinical Trials by Zone, 2016
- Table 38:Savaysa Historical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 41:SavaysaSales by Atrial Fibrillation (AF) (USD MM)
- Table 39: SavaysaSales by Venous Thromboembolism (VTE) (USD MM)
- Table 41: Savaysa, Clinical Trials by Zone, 2016
- Table 42: LovenoxHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 43: LovenoxSales by Venous Thromboembolism (VTE) (USD MM)
- Table 44:Lovenox, Clinical Trials by Zone, 2016
- Table 45:FraxiparineHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 46: FraxiparineSales by Venous Thromboembolism (VTE) (USD MM)
- Table 47:Fraxiparine, Clinical Trials by Zone, 2016
- Table 48: ArixtraHistorical Sales and Forecasted Sales (2011-2020)(USD MM)
- Table 49: ArixtraSales by Venous Thromboembolism (VTE) (USD MM)
- Table 50:Arixtra, Clinical Trials by Zone, 2016
- Table 51:BetrixabanForecasted Sales (2011-2020)(USD MM)
- Table 52: BetrixabanSales by Venous Thromboembolism (VTE) (USD MM)
- Table 53:Betrixaban, Clinical Trials by Zone, 2016

List of Figures

- Figure 1: Global Anticoagulants Sales- 2015-2020
- Figure 2: Global Anticoagulants Sales by Drugs- 2011-2020
- Figure 3: Global Anticoagulants Market Share by Drugs (%)- 2011-2020
- Figure 4: Global Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 5: Global Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 6: Global Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 7: Global Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 8: US Anticoagulants Sales- 2011-2020
- Figure 9: US Anticoagulants Market Share (%)- 2011-2020
- Figure 10: US Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 11: US Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 12: US Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 13: US Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 14: EU5 Anticoagulants Sales- 2011-2020
- Figure 15: EU5 Anticoagulants Market Share (%)- 2011-2020
- Figure 16: EU5 Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 17: EU5 Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 18: EU5 Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 19: EU5 Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 20: Japan Anticoagulants Sales- 2011-2020
- Figure 21: Japan Anticoagulants Market Share (%)- 2011-2020
- Figure 22: Japan Anticoagulants Sales in Atrial Fibrillation- 2011-2020
- Figure 23: Japan Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
- Figure 24: Japan Anticoagulants Sales in Venous Thromboembolism- 2011-2020
- Figure 25: Japan Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
- Figure 26: Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 27: Xarelto Sales by Atrial Fibrillation (AF)(USD MM)
- Figure 27: Xarelto Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 29: Xarelto, Clinical Trials by Zone (%), 2016
- Figure 30: Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 31: PradaxaSales by Atrial Fibrillation (AF)(USD MM)
- Figure 32: Pradaxa Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 33: Pradaxa, Clinical Trials by Zone (%), 2016
- Figure 34: Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 35: EliquisSales by Atrial Fibrillation (AF)(USD MM)
- Figure 35: Eliquis Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 37: Eliquis, Clinical Trials by Zone (%), 2016
- Figure 38: SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 39: SavaysaSales by Atrial Fibrillation (AF)(USD MM)
- Figure 39: Savaysa Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 41: Savaysa, Clinical Trials by Zone (%), 2016
- Figure 42: Lovenox Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 43: Lovenox Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 44: Lovenox, Clinical Trials by Zone (%), 2016
- Figure 45: Fraxiparine Historical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 46: Fraxiparine Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 47: Fraxiparine, Clinical Trials by Zone (%), 2016
- Figure 48: ArixtraHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
- Figure 49: Arixtra Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 50: Arixtra, Clinical Trials by Zone (%), 2016
- Figure 51: BetrixabanForecasted Sales (2011-2020) (USD MM)
- Figure 52: Betrixaban Sales by Venous Thromboembolism (VTE)(USD MM)
- Figure 53: Betrixaban, Clinical Trials by Zone (%), 20169: EU5 Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 20: Japan Anticoagulants Sales- 2011-2020
Figure 21: Japan Anticoagulants Market Share (%)- 2011-2020
Figure 22: Japan Anticoagulants Sales in Atrial Fibrillation- 2011-2020
Figure 23: Japan Anticoagulants Market Share (%) in Atrial Fibrillation - 2011-2020
Figure 24: Japan Anticoagulants Sales in Venous Thromboembolism- 2011-2020
Figure 25: Japan Anticoagulants Market Share (%) in Venous Thromboembolism - 2011-2020
Figure 26: Xarelto Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 27: Xarelto Sales by Atrial Fibrillation (AF)(USD MM)
Figure 27: Xarelto Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 29: Xarelto, Clinical Trials by Zone (%), 2016
Figure 30: Pradaxa Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 31: PradaxaSales by Atrial Fibrillation (AF)(USD MM)
Figure 32: Pradaxa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 33: Pradaxa, Clinical Trials by Zone (%), 2016
Figure 34: Eliquis Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 35: EliquisSales by Atrial Fibrillation (AF)(USD MM)
Figure 35: Eliquis Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 37: Eliquis, Clinical Trials by Zone (%), 2016
Figure 38: SavaysaHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 39: SavaysaSales by Atrial Fibrillation (AF)(USD MM)
Figure 39: Savaysa Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 41: Savaysa, Clinical Trials by Zone (%), 2016
Figure 42: Lovenox Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 43: Lovenox Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 44: Lovenox, Clinical Trials by Zone (%), 2016
Figure 45: Fraxiparine Historical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 46: Fraxiparine Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 47: Fraxiparine, Clinical Trials by Zone (%), 2016
Figure 48: ArixtraHistorical Sales and Forecasted Sales (2011-2020) (USD MM)
Figure 49: Arixtra Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 50: Arixtra, Clinical Trials by Zone (%), 2016
Figure 51: BetrixabanForecasted Sales (2011-2020) (USD MM)
Figure 52: Betrixaban Sales by Venous Thromboembolism (VTE)(USD MM)
Figure 53: Betrixaban, Clinical Trials by Zone (%), 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
- Aspen Pharmaceuticals
- Bayer
- Boehringer Ingelheim
- Bristol-Myers Squib
- Daiichi Sankyo
- Glaxosmithkline
- Janssen Pharmaceutica
- Portola Pharmaceuticals
- Sanofi-Aventis
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll